Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
ST. LOUIS, May 04, 2018 -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14, 2018 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2018 financial results conference call | |||||||
| When: | Monday, May 14th at 10:00 a.m. Eastern Time (7:00 a.m. PT) | |||||||
| Dial In Number: | To access the live call, dial 800-289-0438 (US and Canada) or 323-794-2423 (International) and give the participant pass code 7909480. | |||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com. | |||||||
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 21, 2018. To access the replay dial-in information, please click here. | |||||||
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
314-678-6100
[email protected]
